<DOC>
	<DOCNO>NCT02102438</DOCNO>
	<brief_summary>There major concern regard chemotherapy related toxicity group woman older 65 year old diagnose human epidermal growth factor receptor 2 ( HER2 ) positive breast cancer ( BC ) . Nevertheless , patient particularly high risk breast cancer recurrence death . Of note , old patient may experience high risk Trastuzumabe related cardiotoxicity , especially agent combine anthracycline . Recent study show extremely favourable outcome early HER2+ BC patient treat combination paclitaxel trastuzumab , omit anthracyclines treatment . Investigators seek investigate safety outcome data cohort elderly patient treat weekly paclitaxel combine carboplatin trastuzumab .</brief_summary>
	<brief_title>Chemotherapy Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer</brief_title>
	<detailed_description>Breast cancer common female cancer second common cause cancer death woman . BC incidence markedly increase age . Amplification overexpression HER2 oncogene present approximately 18 20 % primary invasive BC . In absence HER2 target therapy combine adjuvant neoadjuvant chemotherapy , HER2 overexpression amplification associate high rate disease recurrence death . There major concern regard chemotherapy related toxicity group woman older 65 year old diagnose HER2 positive breast cancer . Nevertheless , patient particularly high risk breast cancer recurrence death . Of note , old patient may experience high risk Trastuzumabe related cardiotoxicity , especially agent combine anthracycline . Recent study show extremely favourable outcome early HER2+ BC patient treat combination paclitaxel trastuzumab , omit anthracyclines treatment . Investigators seek investigate safety outcome data cohort elderly patient treat weekly paclitaxel combine carboplatin trastuzumab .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Clinical Pathological Stage I IIIA breast adenocarcinoma . HER2 overexpression amplification define immunohistochemistry stain +3 positive fluorescence situ hybridization ( FISH ) test . Age ≥ 65 year old . WHO performance status le 2 ; adequate hematologic ( granulocyte count ≥ 2 X 109/L , platelet count ≥100 X109/L ) hepatic ( transaminases ≤ 1.5 X upper limit normal ( ULN ) , alkaline phosphatase ≤ 2.5 time ULN , bilirubin ≤ ULN ) test ; normal cardiac function ( baseline leave ventricular ejection fraction least ≥ 55 % ) Radiologic image metastatic disease . History cardiac disease contraindicate anthracyclines , uncontrolled essential hypertension diabetes , stroke comorbidity could potentially compromise chemotherapy treatment , chronic obstructive pulmonary disease . Any previous treatment anti HER2 therapy .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Elderly patient</keyword>
	<keyword>Localized HER2+ Breast Cancer</keyword>
	<keyword>Omission anthracyclines</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>Adjuvant chemotherapy</keyword>
	<keyword>Safety information</keyword>
</DOC>